Kardigan, Inc.

NASDAQ:KARD

Biotechnology

Healthcare
$12.32 +3.50%

+$0.77 today

Market cap
$1.10B
Beta
0.00
52W Low $16.25High $24.00

Volume 0.55M

Average 5.84M

KARD Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

No reported Stock-Based Compensation figures are available to summarize.

Stock-Based Compensation history

Currency unavailable · from the cash flow

No Stock-Based Compensation data reported for this period type.

Stock-Based Compensation vs competitors

How KARD compares with its peers on the latest reported figures

KARD Competitors
Stock-Based Compensation for KARD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYTKCytokinetics, IncorporatedLTM Jun 2026$96.8M USD-5.7%+32.9%136.4%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$33.39M USD-16.1%+143.5%468.9%
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$18.83M USD+85.9%+222.1%—
TNYATenaya Therapeutics, Inc.LTM Mar 2026$11.51M USD-28.1%+4.4%5116.0%
RNAAtrium Therapeutics, Inc.FY2025$7.68M USD——41.2%
KARDKardigan, Inc.—— ———
Peer median (excluding KARD) —-10.9%+88.2%302.7%

Competitors are the stored peer set for KARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kardigan, Inc.

NASDAQ:KARD

Intrinsic Alpha fair value

Locked

Current Price

$12.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.